Pipeline

Mode of action	Product Candidate or Program	Indication	Discovery	Pre-clinical	Phase 1	Phase 2	Phase 3 / Pivotal
Cancer metabolism Tumor starvation	eryaspase /GRASPA® (asparaginase)	2L Advanced PAC	TRYbeCA-1
		Hypersensitive ALL	NOPHO IST
		Advanced TNBC	TRYbeCA-2
		1L Advanced PAC
	erymethionase (Methionine-γ-Lyase)	Solid Tumors
Immune modulation	Immuno-oncology Tolerance induction	Solid tumors*
Enzymes replacement	Therapeutic enzymes	Metabolic diseases

ALL: acute lymphoblastic leukemia; PAC: pancreatic cancer; TNBC: triple-negative breast cancer; 1L: first line; 2L: second line; IST: Investigator-sponsored trial; NOPHO: Nordic Society of Paediatric Haematology and Oncology; * Développé par SQZ Biotech